Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Galectin 3 Antibodies:
anti-Rat (Rattus) Galectin 3 Antibodies:
anti-Mouse (Murine) Galectin 3 Antibodies:
Go to our pre-filtered search.
Human Polyclonal Galectin 3 Primary Antibody for CyTOF, FACS - ABIN4899436
Thijssen, Hulsmans, Griffioen: The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. in The American journal of pathology 2008
Show all 5 Pubmed References
Human Monoclonal Galectin 3 Primary Antibody for IHC (f), ICS - ABIN2689513
Cherayil, Weiner, Pillai: The Mac-2 antigen is a galactose-specific lectin that binds IgE. in The Journal of experimental medicine 1990
Show all 4 Pubmed References
Human Monoclonal Galectin 3 Primary Antibody for Func, IA - ABIN2192045
Liu, Hsu, Zuberi, Hill, Shenhav, Kuwabara, Chen: Modulation of functional properties of galectin-3 by monoclonal antibodies binding to the non-lectin domains. in Biochemistry 1996
Show all 3 Pubmed References
Human Polyclonal Galectin 3 Primary Antibody for IF (p), IHC (p) - ABIN672321
Lee, Bae, Choi, Park, Chun: Molecular cloning and expression analysis of pig CD7. in Veterinary research communications 2014
Show all 2 Pubmed References
Human Monoclonal Galectin 3 Primary Antibody for ELISA, FACS - ABIN152697
Staels, Rubenstrunk, Noel, Rigou, Delataille, Millatt, Baron, Lucas, Tailleux, Hum, Ratziu, Cariou, Hanf: Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. in Hepatology (Baltimore, Md.) 2013
Show all 2 Pubmed References
Mouse (Murine) Monoclonal Galectin 3 Primary Antibody for FACS - ABIN4896110
Ansa-Addo, Lange, Stratton, Antwi-Baffour, Cestari, Ramirez, McCrossan, Inal: Human plasma membrane-derived vesicles halt proliferation and induce differentiation of THP-1 acute monocytic leukemia cells. in Journal of immunology (Baltimore, Md. : 1950) 2010
Show all 2 Pubmed References
Human Polyclonal Galectin 3 Primary Antibody for ELISA, WB - ABIN2473746
Dumic, Dabelic, Flögel: Galectin-3: an open-ended story. in Biochimica et biophysica acta 2006
Mouse (Murine) Monoclonal Galectin 3 Primary Antibody for EIA, FACS - ABIN114277
Knisley, Weitlauf: Compartmentalized reactivity of M3/38 (anti-Mac-2) and M3/84 (anti-Mac-3) in the uterus of pregnant mice. in Journal of reproduction and fertility 1993
Show all 12 Pubmed References
Human Polyclonal Galectin 3 Primary Antibody for WB - ABIN517489
Shi, Tan, Meng, Yu, Li, Yin, Wei, Luo, Jia, Zhang, Wu, Mi, Wang: Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus. in Arthritis & rheumatology (Hoboken, N.J.) 2014
Cow (Bovine) Polyclonal Galectin 3 Primary Antibody for IHC, WB - ABIN2785832
Bartolazzi, Orlandi, Saggiorato, Volante, Arecco, Rossetto, Palestini, Ghigo, Papotti, Bussolati, Martegani, Pantellini, Carpi, Giovagnoli, Monti, Toscano, Sciacchitano, Pennelli, Mian, Pelizzo, Rugge, Troncone, Palombini, Chiappetta, Botti, Vecchione, Be: Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. in The lancet oncology 2008
Show all 2 Pubmed References
Demonstrate that galectin-3 plays a critical role in hensin ECM assembly by oligomerizing secreted monomeric hensin.
Rs2274273 and rs17128183 rare allele bearing genotypes, according to the dominant model (CT+TT vs. CC and AG+GG vs. AA, respectively), were significantly and independently associated with maladaptive LVR (adjusted OR = 3.02, P = 0.016; adjusted OR = 3.14, P = 0.019, respectively) and higher LGALS-3 mRNA expression
galectin-3C enhances galectin-3 binding to neutrophils by nonactivating type-C self-association, in parallel to inhibiting neutrophil activation by galectin-3 (induced by type-N self-association).
Galectin-3 plays a role in the systemic immune system response against Helicobacter pylori (Hp,) potentiating its deleterious effect in areas distant from gastrointestinal tract colonization and may contribute to triggering CNS inflammation and/or neurodegeneration.
Pull-down assays, gel filtration, and biolayer interferometry further demonstrate that galectin-3 binds to the CD146 ectodomain (eFL) with a KD of ~1.1 mum.
Gal-3 contributes to the pathogenesis of ocular allergy and represents a relevant therapeutic target.
findings increase understanding as to how galactans interact with Gal-3 at the non-reducing, terminal end of galactose-containing polysaccharides as found on the cell surface.
Low galectin 3 expression is associated with Thyroid Papillary Carcinoma.
Data indicate a high expression of galectin-9 (Gal-9) in pancreatic ductal adenocarcinoma (PDAC) serum and tissue.
The TGF-beta-induced epithelial-mesenchymal transition in A549 cells can be enhanced by Galectin3.
Study report that galectin3 expression is upregulated in nonsmall cell lung cancer cells under hypoxia and that it contributes to tumor cell migration and invasion. Cell motility is upregulated by the function of activated RhoA, which is induced by high levels of cytoplasmic galectin3.
Serum galectin-3 is independently associated with progressive renal disease in type 2 diabetes
Galectin-3 levels independently predict outcomes in patients with reduced left ventricular systolic function addressed for ablation of persistent atrial fibrillation, and may be of interest in defining the therapeutic strategy in this population.
These results suggest that Gal-3 expression is closely correlated with HIV-1 expression in latently infected cells through NF-kappaB activation and that it interacts with HIV-1 Tat.
Our study confirms that galectin-3 inhibits the sensitivity of human epithelial ovarian cancer OVCAR-3 cells to cisplatin, via inhibiting the cisplatin-mediated growth reduction, apoptosis induction and mitochondria dysfunction. This implies that galectin-3 might be an effective target to sensitize ovarian cancer cells to chemotherapy.
mDectin-1, mDectin-2, and SIGN-R1 are decorated by N-glycan structures that can be recognized by the carbohydrate recognition domain of Gal-3.
Study confirmed that galectin-3 as a ligand of TLR4 induced TLR4 signaling activation in lung adenocarcinoma cells, thereby activating downstream p65 nucleus translocation, promoting NEAT1 expression, and finally affecting lung adenocarcinoma cell proliferation and migration.
Results show that Gal-3 is highly upregulated in human gastric adenocarcinoma (GAC) and that Gal-3 upregulates c-MYC through increasing RalA activity and its binding to YAP1 which contribute to aggressive phenotype; novel YAP1 inhibitor and BET inhibitor effectively block Gal-3-mediated phenotype. Also, Gal-3 is an independent prognostic marker of shorter overall survival.
results demonstrate that human resting NK cells express Gal-3 at both gene and protein levels and that the Gal-3 expression can be modulated upon cytokine stimulation. In the same cells, Gal-3 always localizes intracellularly and functionally correlates with the degree of NK cell degranulation.
Interaction between galectin-3 and its potential inhibitor, bergenin, was studied using computational methods.
It has been reported that the Galectin-3/NuMA interaction is functionally important for the spindle pole organization; spindle pole cohesion requires glycosylation-mediated localization of NuMA.
Mutational tuning of galectin-3 specificity and biological function.
The overall findings suggest that the secreted galectin-3 stimulated by PGF plays a role in structural luteolysis by binding to beta 1 integrin.
The relative abundance of PIBF, LGALS1, LGALS3, LGALS3BP, and LGALS9 mRNA would display a differential expression pattern in the endometrium.
endogenous galectin-3 enhances the effects of H5N1 infection by promoting host inflammatory responses and regulating IL-1beta production by macrophages via interaction with NLRP3.
this study shows that decrease of galectin-3 in keratinocytes is a potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis
Compared with WT mice, Gal-3 KO mice have more germinal centers B cells and T follicular helper cells, increased percentages of antibody-secreting cells and higher concentrations of immunoglobulins and IFN-gamma in serum, and develop a lupus-like disease.
Evidence for a contribution of galectin-3 to bone cell maturation and function, bone remodeling, and biomechanical competence, thus identifying galectin-3 as a promising therapeutic target for age-related disorders of bone remodeling.
Robust upregulation of cardiac galectin-3 (Gal-3) expression in a mouse model of cardiomyopathy attributable to cardiomyocyte-restricted transgenic activation of beta2-adrenoceptors may not be a critical disease mediator of cardiac remodeling in this model.
Galectin-3 suppresses antibacterial autophagy through a host N-glycan-dependent mechanism in Listeria-infected macrophages. Knock out of the galectin-3 gene resulted in enhanced LC3 recruitment to Listeria and decreased bacterial replication.
Study shows that potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin alpha2 chain-deficient muscular dystrophy.
These results suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other proteins, to TLR-4 and promoting inflammation and neuronal loss.
Gal-3 and nSMase, by inducing thyroid changes, might be the cause of the increased expression and altered distribution of TSH, thyroglobulin, and TSHR or vice-versa.
Stroke (after left sided permanent middle cerebral artery occlusion) triggers central and peripheral galectin-3 release causing enteric neuronal loss through a TLR4 mediated mechanism involving TAK1 and AMPK.
the secretion of galectin-3 as a novel mechanism for osteoblasts to control osteoclastogenesis and to maintain trabecular bone homeostasis independently of the RANKL/OPG-axis.
Our findings establish gal-3 as a molecular regulator of the JAG1/Notch-1 signaling pathway and have direct implications for the development of strategies aimed at controlling tumor angiogenesis.
Mycobacerium PtkA downregulates host Galectin 3, which is an anti-apoptotic molecule.
Antilymphoma activity by M(IFN-gamma/LPS) macrophages was mediated, in part, by galectin-3. Intriguingly, aggressive lymphoma growth was markedly impaired in mice deficient in galectin-3, suggesting either that host galectin-3-mediated antilymphoma activity is required to sustain net tumor growth or that additional functions of galectin-3 drive key oncogenic mechanisms in non-Hodgkin's lymphoma.
galectin-3 is dynamically overexpressed in response to acute myocardial infarction-induced cardiac remodelling.
Lgals3, a PRC2 target gene encoding a multifunctional galactose-binding lectin, was derepressed in I363M heterozygotes, which enhanced the stemness of HSPCs. Thus, our work provides in vivo evidence that the structural integrity of EED to H3K27me3 propagation is critical, especially for embryonic development and hematopoietic homeostasis, and that its perturbation increases the predisposition to hematologic malignancies.
Increased galectin-3 levels are associated with abdominal aortic aneurysm progression. Galectin-3 inhibition with modified citrus pectin prevented AAA development.
Data suggest that different patterns of Pkd1-deficiency can lead to cardiac dysfunction and that galectin-3 has a role in intensifying this phenotype and limiting survival, effects potentially applicable to human autosomal dominant polycystic kidney disease.
This gene encodes a member of the galectin family of carbohydrate binding proteins. Members of this protein family have an affinity for beta-galactosides. The encoded protein is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. This protein can self-associate through the N-terminal domain allowing it to bind to multivalent saccharide ligands. This protein localizes to the extracellular matrix, the cytoplasm and the nucleus. This protein plays a role in numerous cellular functions including apoptosis, innate immunity, cell adhesion and T-cell regulation. Alternate splicing results in multiple transcript variants.
35 kDa lectin
, beta-galactosides-binding lectin
, carbohydrate-binding protein 35
, galactose-specific lectin 3
, igE-binding protein
, laminin-binding protein
, lectin L-29
, lectin, galactoside-binding, soluble, 3 (galectin 3)
, mac-2 antigen
, 3 (galectin 3)
, CBP 35
, IgE-binding protein
, MAC-2 antigen
, lectin, galactoside-binding, soluble, 3
, galectin 3
, IgE binding protein
, lectin, galactose binding, soluble 3
, L-34 galactoside-binding lectin